[title missed]

Corresponding author: shengxiaosheng, sxsjhzj@163.com

DOI: 10.12201/bmr.202501.00078

•  

  Abstract: Objective To investigate the effect of polymorphism at the -94ins/del ATTG (rs28362491) site in the promoter region of nuclear transcription factor-κB1 (NF-κB1) on the lipid-lowering and anti-inflammatory efficacy of atorvastatin in patients with coronary heart disease(CHD). Method A total of 180 CHD patients from Jinhua PeoplesHospital in Zhejiang Province from June 2022 to June 2024 were selected as the study subjects and treated with atorvastatin calcium 20 mg·d-1.Detect the genotype of the NF-κB1 gene rs28362491 locus, analyze the levels of blood lipids and inflammatory factors in patients before medication,1and 6 months after medication,and observe the occurrence of adverse reactions during treatment. Results,180 CHD patients underwent genetic testing and were divided into DD type 46, ID type 76, and II type 58. The genotype distribution followed Hardy Weinberg equilibrium (P＞0.05). Before treatment, there was no significant difference in high density lipoprotein cholesterol (HDL-C) levels among the three groups (P＞0.05);The levels of total cholesterol (TC),low density lipoprotein cholesterol(LDL-C), interleukin-6(IL-6), interleukin-8(IL-8),and tumor necrosis factor-α (TNF-α) in DD type were higher than those in ID type and II type (P＜0.05), while there was no significant difference in TC, LDL-C, IL-6, IL-8, and TNF-αlevels between ID type and II type (P＞0.05). After 1 and 6 months of treatment, the levels of TC, LDL-C,IL-6,IL-8, and TNF -α in the three groups of patients decreased significantly compared to before treatment (P＜0.05);At the same time point,the change rates of TC,LDL-C,IL-6,IL-8,and TNF-αlevels in ID and II types were higher than those in DD type (P＜0.05).Within six months of follow-up,there was no significant difference in the incidence of gastrointestinal symptoms, muscle symptoms,liver symptoms, and neurological symptoms among different genotypes (P＞0.05).Conclusion The efficacy of atorvastatin in CHD patients is associated with the rs28362491 polymorphism of the NF-κB1 gene,with II and ID genotypes showing better efficacy than DD genotypes.

  Key words: Gene polymorphism; Coronary heart disease; Atorvastatin; Blood lipid

  Submit time: 26 January 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• ZHANG Yi-ying, DU Yu, LI Meng, LI Yuan-bai, YANG Shuo, Liu Fang-zhou, WANG Jing, LI Yi-hao, YANG Yang. Analysis of the characteristics of ancient prescriptions for coronary heart disease based on association rules. 2021. doi: 10.12201/bmr.202110.00027

  NIU Xiao Shan. Advances in pharmacological studies of NF-κB involved in the regulation of nonalcoholic fatty liver disease. 2024. doi: 10.12201/bmr.202410.00006

  Zhangshaoqiang. Network Meta-analysis of Different Efficacy Combinations of Traditional Chinese Medicine Compounds Combined With Conventional Western Medicines in the Treatment of Coronary Heart Disease Combined with Depression. 2024. doi: 10.12201/bmr.202410.00055

  张丽霞, LANG Zegao, WANG Hui. Correlation between SIRT1/NF-κB signaling pathway and cognitive impairment in patients with Parkinsons disease. 2024. doi: 10.12201/bmr.202412.00077

  SUI XIN, SONG JUAN, BAO YANAN, LIN YU, MAN ZITENG, CHENG TIANTIAN, YANG HONGYAN. 1. School of Pharmacy,Qiqihar Medical University,Qiqihar 161006,China2. Affiliated Third Hospital,Qiqihar Medical University,Qiqihar 161006,China. 2024. doi: 10.12201/bmr.202407.00036

  Wangzhong. Correlation of Serum soluble TREM2 with Acute coronary syndrome in the elderly. 2024. doi: 10.12201/bmr.202412.00086

  A Study on the Prediction of Acute Coronary Syndrome Based on Coronary Fat Attenuation Index and Laboratory Indicators. 2024. doi: 10.12201/bmr.202409.00001

  wang zhong. Plasma C1q/ tumor necrosis factor-associated protein 6 and systemic inflammatory response index levels in patients with heart failure and their clinical significance. 2025. doi: 10.12201/bmr.202501.00060

  Wu Xiayang. Evaluation of the effectiveness and safety of generic and original azithromycin for the treatment of pediatric mycoplasma pneumonia. 2025. doi: 10.12201/bmr.202501.00071

• ID	Submit time	Number	Download
  1	2025-01-06	bmr.202501.00078V1	Download

• Public  Anonymous  To author only Submit Comments